CD155-based chimeric antigen receptor T cells: a promising immunotherapy for cervical and breast cancer
Overall, our findings provide strong evidence for the efficacy and safety of CD155-based CAR T-cell therapy in cervical and breast cancer. This study contributes to the growing body of research supporting the potential clinical application of CD155-targeted immunotherapy for patients with cervical and breast cancer.
Authors
- Xin Zhao (ORCID: https://orcid.org/0000-0001-7525-4097)
- Qianqian Shi (ORCID: https://orcid.org/0000-0002-5266-6731)
- Yang-Nan Ding
- Wenjing Zhu (ORCID: https://orcid.org/0000-0003-0958-0905)
- Jun Ma (ORCID: https://orcid.org/0000-0002-1137-9349)
- Rui Zhao (ORCID: https://orcid.org/0000-0002-6602-6583)
- Yang Fang (ORCID: https://orcid.org/0000-0001-7042-5133)
- Kai Zhang (ORCID: https://orcid.org/0000-0003-3730-5011)
- Enwu Yuan (ORCID: https://orcid.org/0000-0002-7378-5043)
Institutions
- Zhengzhou University (CN)
- Third Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-19
- DOI
- https://doi.org/10.3389/fimmu.2025.1631812
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China